ZappRx and Teva Respiratory Collaborate to Speed Delivery of Specialty Medication

February 12, 2019

Partnership provides physicians using the ZappRx prescribing platform with a streamlined way to prescribe respiratory medication and provide access to associated programs


Boston, MA, February 12, 2019 ZappRx®, a healthcare technology company that streamlines the complex processes associated with prescribing specialty medications, announced today that it will work with Teva Respiratory, LLC, in support of their specialty respiratory medication. The joint project will provide a more efficient approach to prescribe, obtain, and administer therapy necessary for patients to better manage their disease and symptoms.


“By partnering with industry leaders such as Teva Respiratory, ZappRx is able to make life-changing medications more accessible to an underserved patient population,” said Zoë Barry, CEO and Founder of ZappRx. “ZappRx is committed to helping patients first and foremost, and we are confident that working with Teva will help us to do exactly that.”


ZappRx’s cloud-based platform streamlines what is currently a multi-step, manual prescribing process, often involving numerous platforms for each of several treatments, into a single, digitally-enabled format. This allows providers who treat severe asthma to focus more on patient care.


To learn more about ZappRx and the work it is doing to improve care for patients in need, visit them online at


About ZappRx

ZappRx streamlines the complex process required to order specialty medications, increasing efficiencies when collecting and maintaining the myriad requisite information for ordering specialty drugs — including pharmacy information, payer/prior authorization requirements, and relevant clinical history.  ZappRx then enables providers, pharmacists, and payers to digitally interact with one another to fill a prescription, reducing the need for faxes and phone calls.  The platform currently is live in Pulmonary (including Cystic Fibrosis (CF), Pulmonary Arterial Hypertension (PAH), and Idiopathic Pulmonary Fibrosis (IPF)), Severe Asthma, Cardiology (including Hyperlipidemia and Congestive Heart Failure), and Gastroenterology (including Crohn’s Disease and Ulcerative Colitis). As the company grows, ZappRx plans to expand into other areas, including Rheumatology, Neurology, and Oncology.


Connect with ZappRx on Twitter and LinkedIn.



ZappRx and the "Z" logo are registered trademarks of ZappRx, Inc. 



Matter for ZappRx

Jessica Wolter